RemeGen CoREGMF -6.23%41 EBITDA Margin % is 104.74% as of Dec. 2025. GuruFocus rates REGMF with a GF Score™ of 41/100 and a GF Value™ of $31.89 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 944 Biotechnology companies, RemeGen Co ranks better than 96.29% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. RemeGen Co's EBITDA for the
three
months ended in Dec. 2025 was $226.3 Mil. RemeGen Co's Revenue for the
three
months ended in Dec. 2025 was $216.1 Mil. Therefore, RemeGen Co's EBITDA margin for the quarter that ended in Dec. 2025 was 104.74%.
RemeGen Co (OTCPK:REGMF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
RemeGen Co EBITDA Margin % Related Terms
RemeGen Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for RemeGen Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
REGMF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, RemeGen Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where RemeGen Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co (REGMF) has a EBITDA Margin % of 104.74% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on RemeGen Co and its competitors. According to the industry distribution chart, RemeGen Co ranks #35 out of 944 companies in the Biotechnology industry, placing it in the top 3.7%.
Is RemeGen Co's EBITDA Margin % too high?
RemeGen Co's current EBITDA Margin % is 104.74%. Based on the distribution chart, RemeGen Co ranks #35 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, RemeGen Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #35 out of 944 companies for EBITDA Margin %. This places RemeGen Co in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on RemeGen Co and its competitors. RemeGen Co's current EBITDA Margin % is 104.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (REGMF) is currently considered Possible Value Trap. The stock's GF Value™ is $31.89, compared to a current price of $12.05 — trading 62.2% below its estimated fair value. The current EBITDA Margin % is 104.74%. RemeGen Co's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For RemeGen Co (REGMF), the current EBITDA Margin % is 104.74% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RemeGen Co (REGMF) Overvalued in 2026?
Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued.
The current stock price of $12.05 is trading 62.2% below its estimated GF Value™ of $31.89.
GuruFocus considers RemeGen Co to be Possible Value Trap.
Key valuation signals for REGMF:
EBITDA Margin %: 104.74%
GF Value™: $31.89 vs. price of $12.05 (62.2% below fair value)
No single metric tells the full story. See the REGMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
41GF Score
Get the complete analysis for REGMF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REGMF has been successfully added to your 
